NICE backs selective internal radiation therapy for advanced liver cancer
Hundreds of people will be able to benefit from this treatment type
Read More
Tag: sorafenib
BMS’ Opdivo disappoints in late-stage trial
However, a clear trend was demonstrated towards improvement in overall survival.
Read More
MSD’s Keytruda approved for liver cancer
US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Read More
Lenvima backed for NHS use to treat liver cancer
NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and Wales as an option for a type of untreated, advanced liver cancer.
Read More
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
Read More
NICE rejects Bayer’s Nexavar for liver cancer
Bayer’s Nexavar is the latest medicine currently available through the Cancer Drugs Fund that has failed to meet cost-effectiveness standards set by the National Institute for Health and Care Excellence.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
